Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

1,3-Di-HABA Kanamycin A

1,3-Di-HABA Kanamycin A is listed in the pharmaceutical impurity collection under CAS 927821-99-6. Its represented structure has formula C26H50N6O15 and a calculated molecular weight of 686.71 g/mol.

2D chemical structure

N H 2 O H O N H H N O O H N H 2 O O O H H O H 2 N O H O H O O N H 2 O H O H O H ( S ) ( S ) ( R ) ( S ) ( S ) ( S ) ( R ) ( S ) ( S ) ( R ) ( R ) ( R ) ( R ) ( R ) ( S ) ( S ) ( R )

Chemical identity

Catalog name
1,3-Di-HABA Kanamycin A
Common name
1,3-Di-HABA Kanamycin A
Chemical name
(2S)-4-amino-N-[(1R,2S,3R,4R,5S)-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[[(2S)-4-amino-2-hydroxybutanoyl]amino]-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
CAS
927821-99-6
SMILES
NCC[C@H](O)C(=O)N[C@H]1C[C@@H](NC(=O)[C@@H](O)CCN)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@@H](O)[C@@H]1O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O
InChI
InChI=1S/C26H50N6O15/c27-3-1-10(34)23(42)31-8-5-9(32-24(43)11(35)2-4-28)22(47-26-19(40)18(39)16(37)12(6-29)44-26)20(41)21(8)46-25-17(38)14(30)15(36)13(7-33)45-25/h8-22,25-26,33-41H,1-7,27-30H2,(H,31,42)(H,32,43)/t8-,9+,10+,11+,12-,13-,14+,15-,16-,17-,18+,19-,20-,21+,22-,25-,26-/m1/s1
InChIKey
HVNATBKIPCIZAA-NVZIBTGPSA-N
Associated API
Amikacin

Record ID: Adf0acad30b16

Computed properties

C26H50N6O15 Molecular formula
686.713 g/molMolecular weight
686.3334 DaMonoisotopic exact mass
381.27 ŲTopological polar surface area
-9.557 Calculated LogP (Wildman–Crippen)
155.0592 cm³/molMolar refractivity (Wildman–Crippen)
19 countHydrogen-bond acceptors
15 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 6 12 18 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C H N O 0 15 30 45 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight686.71394.65
Calculated LogP (Wildman–Crippen)-9.5570.37
Topological polar surface area381.2799.21
Hydrogen-bond acceptors1999.40
Hydrogen-bond donors1599.50
Rotatable bonds (strict)1495.92

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC26H50N6O15dimensionless
Molecular weight686.713g/mol
Monoisotopic exact mass686.3334Da
Topological polar surface area381.27Ų
Calculated LogP (Wildman–Crippen)-9.557dimensionless
Molar refractivity (Wildman–Crippen)155.0592cm³/mol
Hydrogen-bond acceptors19count
Hydrogen-bond donors15count
Rotatable bonds (strict)14count
Heavy atoms47count
Heteroatoms21count
Rings3count
Aromatic rings0count
Aliphatic rings3count
Saturated rings3count
Aromatic heterocycles0count
Aliphatic heterocycles2count
Saturated heterocycles2count
Aromatic carbocycles0count
Aliphatic carbocycles1count
Fraction of sp³ carbon atoms0.9231fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters17count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area269.2299Ų
Valence electrons274count
Radical electrons0count
Bertz complexity928.4261index
Balaban J2.0015index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for 1,3-Di-HABA Kanamycin A

Qualification and safety assessment of 1,3-Di-HABA Kanamycin A

Explore toxicological qualification of 1,3-Di-HABA Kanamycin A and ICH M7 mutagenic impurity assessment of 1,3-Di-HABA Kanamycin A for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for 1,3-Di-HABA Kanamycin A and acceptable intake and limit justification for 1,3-Di-HABA Kanamycin A. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Other catalogue designations with the same represented structure

These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for 1,3-Di-HABA Kanamycin A

Explore Altox services and software through the Altox Pharma-Hub.